mRNAをベースとするがんワクチンが、膵臓がん患者を対象とした小規模治験で印象的な成果を上げ、手術後の再発リスクを低減する長期的な免疫反応を誘導（刺激）できる可能性を示唆している。 mRNAワクチン「autogene ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The previously-unknown condition, dubbed 'post-vaccination syndrome' (PVS), can persist years after taking the Covid vaccines ...

Currently, the most widely used vaccine against TB is the Bacillus Calmette-Guérin (BCG). Developed in 1921, the vaccine ...

今回の見直しは、メッセンジャーＲＮＡ（ｍＲＮＡ）ワクチンへの支出を精査する政府の取り組みの一環。鳥インフルエンザワクチンの研究開発に対する追加支援はバイデン前政権の最後の数日間で締結され、モデルナの株価は１月17日の発表後２営業日で13％上昇した。

The approval of AIM Vaccine's mRNA RSV vaccine for clinical trials in the U.S. is seen by analysts as further validation of the company's "Innovation + Expansion" capabilities, potentially providing ...

As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in ...

A new mRNA vaccine against tuberculosis (TB) is showing favorable results in preclinical trials. With only one currently ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...

Clinical studies suggest that the mRNA vaccine could aid in treating pancreatic cancer, one of the most lethal forms of ...

SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026 Joint R&D project between SK and CEPI includes up to ...